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Summary: CD4 + T-helper cells regulate immunity and inflammation through the acquisition of potential to secrete specific cytokines. The acquisition of cytokine-secreting potential, in a process termed T-helper cell differentiation, is a response to multiple environmental signals including the cytokine milieu. The most recently defined subset of T-helper cells are termed Th9 and are identified by the potent production of interleukin-9 (IL-9). Given the pleiotropic functions of IL-9, Th9 cells might be involved in pathogen immunity and immune-mediated disease. In this review, I focus on recent developments in understanding the signals that promote Th9 differentiation, the transcription factors that regulate IL-9 expression, and finally the potential roles for Th9 cells in immunity in vivo.
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Th9 cells
CD4
+ T-helper cells differentiate into effector subsets in response to environmental cues including cytokines and ligand-receptor interactions from cell-cell contact. These environmental signals promote the development of T-helper (Th) subsets that secrete specific cytokines and perform distinct functions in regulating immunity and inflammation. Th9 cells are one of the more recently described subsets of effector T cells. They develop from naive T cells in the presence of transforming growth factor b (TGFb) and interleukin-4 (IL-4). As the sobriquet would suggest, cells cultured under these conditions are primed for the production of IL-9 and require transcription factors that include STAT6 (signal transducer and activator of transcription 6), PU.1, IRF4 (interferon response factor 4), and GATA3 (1) (2) (3) (4) . In addition to IL-9, Th9 cells have been shown to produce IL-10 and IL-21, although these are not regulated coordinately with IL-9, and their role in Th9 cell function is unclear (1, 2, (4) (5) (6) (7) . Th9 function has been associated with a wide variety of inflammatory disease, and as discussed below, their function does not segregate as neatly as some of the other Th effector subsets. The pleiotropic functions of IL-9 have recently been reviewed extensively (8, 9) , and I do not review those again here.
Instead, I focus on the development and function of Th9 cells, with a particular focus on some of the recent developments in understanding how Il9 is regulated and how IL-9-secreting T cells fit into the spectrum of T-helper effector subsets by addressing some of the outstanding questions regarding Th9 cell biology.
How do Th9 cells develop?
Cytokines
The development of IL-9-secreting T cells is promoted by several cytokines. Foremost among them is IL-4. Several transcription factors downstream of IL-4, including STAT6, GATA3, and IRF4, are required for the differentiation of Th9 cells (2) (3) (4) 10) . However, IL-4 signaling alone leads to Th2 differentiation. The conversion of the Th2-inducing signals into Th9-inducing signals requires signaling from the TGFb receptor superfamily. The TGFb signal, in the absence of IL-4, results in the development of inducible Treg (Tregulatory) cells (11) (12) (13) . TGFb signaling in Th9 cells induces Smad activation and expression of PU.1 (1, 10, 14) . However, the requirement for TGFb signaling may not be absolute. At least one report has shown that IL-9 production during a parasite infection is unaltered by expression of a dominant negative TGFb receptor (15) . One explanation for this may be redundancy with other superfamily members. Indeed, Jones et al. recently showed that Activin A can replace TGFb as a Th9-inducing factor, and in a model of allergic inflammation, both TGFb and Activin needed to be neutralized to see decreases in IL-9 in vivo (16) . Importantly, the development of Th9 cells requires a balance of signals from cytokines that would otherwise generate distinct T-helper subsets.
Various other cytokines also impact T-cell IL-9 production. IL-2, and presumably the downstream factor STAT5, promotes T-cell IL-9 production (17, 18), although it has not yet been determined how important this pathway is for Th9 development in vitro and in vivo. IFNc (interferon-c) inhibits IL-9 production from T cells (18) . A recent report described that CD4 + T cells cultured with TGFb, IL-4, and
IFNc develop into a cell type more closely associated with the Th1 phenotype than with Th9 cells. This differentiation was dependent on T-bet, and the IL-4/STAT6 pathway induced expression of Eomesodermin and resulted in IFNcproducing cells that displayed surface expression of CD103 (19) . Although a population of CD103 + IFNc + T cells is observed among intraepithelial lymphocytes, whether this population has a functional niche in vivo is still not clear.
IL-23 also represses IL-9 production, a conclusion supported both by in vitro culture effects and increased production of IL-9 from Il23r À/À T cells (20, 21) . Given the ability of IL-23 to promote and/or maintain Th17 development and to specifically induce IL-22, it may be an important component of sculpting the cytokine-secreting potential of developing Th17 cells (22) (23) (24) (25) (26) . As Th17 cells have been shown to make some IL-9, albeit not at the levels observed from polarized Th9 cultures, IL-23 might refine cytokine production, directing Th17 cells to more specific functions. IL-1 family members may also contribute to IL-9 production. IL-1 may induce IL-9 under some conditions, and IL-33 is capable of inducing IL-9 in T cells (27) (28) (29) . IL-1 family members induce NF-jB (nuclear factor-jB) activation, which as described later in the review is an important activator of the Il9 gene. IL-1 and IL-1 family members collaborate with other cytokines in cytokine induction. IL-1 synergizes with IL-23 in the induction of IL-17, and IL-18 synergizes with IL-12 in the induction of IFNc (30) . Whether any IL-1 family member synergizes with other cytokines in Il9 induction has not yet been tested.
Finally, strong evidence supports a role for IL-25 in IL-9 production by T cells. Th9 cells express greater amounts of the IL-25 receptor chain IL-17RB than other Th cell subsets suggesting that they are uniquely sensitive to this cytokine (31) . Transgenic IL-25 induces IL-9 production in vivo, and the inflammation that develops in IL-25 transgenic mice is IL-9 dependent (31). Blocking IL-25 in vivo reduces IL-9 production and IL-9-dependent inflammation (31) . Thus, IL-25 plays a critical role in promoting IL-9-dependent immune responses.
The development of Th9 cells requires the integration of multiple signals, and clearly a complex cytokine milieu is required for optimal IL-9 production. At this point, it seems unlikely that all of the cytokine cues that impact Th9 development have been identified, and further work will undoubtedly reveal additional factors that both positively and negatively affect Th9 differentiation.
Costimulation
One of the emerging themes in the development of Th9 cells is the requirement for potent costimulatory signals. In our own unpublished studies, we have observed that TCR (T-cell receptor) transgenic T cells stimulated with peptide on antigen-presenting cells develop very poorly into IL-9-secreting cells in the absence of additional costimulatory signals. Experiments comparing the apoptosis inducing effects of anti-CD28 found that plate-bound anti-CD28 resulted in a greater induction of IL-9 production than cultures stimulated with soluble anti-CD28 (32) . This was at least partly dependent on the induction of endogenous IL-4 and associated with increased expression and phosphorylation of FoxO3a. Whether FoxO3a might directly affect Il9 expression or if this pathway affects survival of cytokine-secreting cells is not clear.
The Notch pathway is required for efficient Th9 development. Conditional deletion of Notch1 and Notch2 decreased IL-9 production in Th9 cultures (14) . Although both are Notch ligands, Jagged2 but not Delta-like 1 was able to induce IL-9 from cells cultured with TGFb alone. Similarly, Jagged2 induced IL-9-dependent immunity in an experimental autoimmune encephalitis (EAE) model, and EAE was attenuated in mice with conditional Notch1 and Notch2 deletion in T cells (14) . The mechanism of Notch-dependent induction of IL-9 is not entirely clear but may involve increased expression of GATA3 because higher concentrations of exogenous IL-4 could overcome the effects of Notch1/2 deficiency. There are also direct effects of the Notch signaling pathway on Il9 as discussed below (14) .
The requirement for additional costimulation in the development of IL-9-secreting T cells was also reported during the process of identifying additional Th9-inducing pathways (33) . Xiao et al. (33) demonstrated a potent ability of the TNFRSF (tumor necrosis factor receptor superfamily) member OX40 to induce IL-9 production, further emphasizing a role for costimulation. The greatest effects of OX40 activation were observed when OX40L was overexpressed on the surface of antigen-presenting cells, resulting in a striking increase in IL-9 production. Induction of IL-9 was specific, as there was no induction of IL-4, and under the respective culture conditions for Treg and Th17 cells, there was OX40-induced repression of Foxp3 (forkhead box protein-3) and IL-17. Importantly, the effects of OX40 were only observed in Th9 culture conditions. The OX40-induced IL-9 effect was also observed in vivo, where OX40L transgene expression and injection of antibody to OX40 resulted in allergic airway inflammation characterized by eosinophil inflammation and goblet cell metaplasia (33) . Although it is not yet known if other TNFSF members can induce IL-9, there are data suggesting that GITR (glucocorticoid-induced TNFR) engagement induces IL-9 from Treg cells (34) , and these results raise the possibility that developing IL-9-secreting T cells will be sensitive to the engagement of a wide array of cytokines and surface receptors.
How is IL-9 regulated?
The Il9 locus is linked to Th2 cytokine loci, about 3.2 Mb telomeric from the Il5 and Il4-Il13 loci. Chromatin at the Il9 promoter is most acetylated in Th9 cells, compared with other T-helper cells, and tri-methylation of H3K27, a repressive chromatin modification, is minimal at the Il9 promoter in Th9 cells, compared with other T-helper subsets (1) . Three conserved non-coding sequences (CNS) have been identified near the Il9 locus. CNS1 is the promoter, and where most factor binding related to gene regulation has been established (1, 35) (Fig. 1) . CNS2 is downstream of Il9 (+5 kb from the transcriptional start), and although the sequence was conserved between murine and human genomes (1), it was not between murine and canine genomes (35) . CNS0 at À6.3 kb from the transcriptional start site is conserved among multiple species. The Il9 promoter (CNS1) has been shown to function in reporter assays and is responsive to multiple factors including IRF4, NF-jB, and Smad/ Notch complexes (3, 14, 33, 36) . The other putative elements have not been tested for regulatory function, although they do reflect changes in chromatin modifications (1, 6, 10). indicating the intron-exon structure and the transcriptional start site from the anti-sense strand, with numbering on mouse chromosome 13 according to GRCm38. Conserved non-coding sequences (CNS) are indicated by red bars, CNS0 is À6.3 kb from the transcriptional start site (TSS), CNS1 is the Il9 promoter, and CNS2 is +5kb from the TSS (1, 35) . The lower schematic indicates the 300 bp, numbered from the TSS, in CNS1. In our previous work, we performed bioinformatics analysis of these sequences; in contrast, this schematic focuses on experimentally determined binding sites for transcription factors that regulate Il9 expression. NF-jB and NFAT sites (À46; À313) were identified by Jash et al. and Xiao et al. (33, 36) . PU.1-binding sites (À194; À309) were determined by Chang et al. (1) . Smad and RBP-Jj sites (À4065 and À4270, respectively) were defined by Elyaman et al. (14) . IRF4 binding and regulation was determined by Staudt et al., and potential binding sites (À100; À240, sense strand orientation) were defined by Perumal and Kaplan (3, 35) .
PU.1 PU.1, encoded in mice by the Sfpi1 locus, is required for optimal Th9 development (1) . PU.1 is expressed in Th9 cells at greater levels than Th1, Th2, or Th17 cells and is induced by the TGFb signaling pathway, independently of IL-4 and STAT6 (1, 10) . PU.1-deficient Th9 cultures have diminished production of IL-9, and decreased Il9 mRNA, compared with wildtype cultures. Transduction of PU.1 into Th9 and Th2 cultures induces IL-9 production, as it decreases Th2 cytokine production (1, 37, 38) . PU.1 function in T cells was first identified by its expression in the IL-4-low subpopulation of Th2 cells (37, 38) . When transduced into Th2 cells, PU.1 diminished expression of most Th2 cytokines, while leaving intact other markers of Th2 cells including expression of CCR4 and GATA3 (38) . Conversely, reducing PU.1 expression, either by shRNA or conditional mutation, resulted in increased Th2 cytokine production, particularly in cells that were positive for more than one cytokine (37, 38) . Based on its ability to inhibit the Th2 phenotype and promote Th9 development, PU.1 is the only factor identified thus far that can convert another T-helper lineage into a Th9 phenotype.
In Th2 cells, PU.1 functions by interfering with GATA3 and IRF4 activity (38, 39) . PU.1 interacts with each of these factors and interferes with their ability to bind DNA and activate transcription. In PU.1-deficient Th2 cells, there is increased binding of GATA3 to the Il4 locus, and IRF4 to the Il10 locus, coincident with increased expression of each cytokine (37, 39) . Thus, although PU.1 is expressed in lower amounts in Th2 cells, compared with Th9 cells, it contributes to the heterogeneity of cytokine expression in the population by modifying the function of Th2 cytokineregulating transcription factors.
In Th9 cells, PU.1 functions by directly binding to the Il9 promoter and recruiting chromatin-modifying enzymes (1, 6) ( Fig. 1) . PU.1-deficient Th9 cultures have decreased total histone H3 acetylation and decreased acetylation of several specific histone residues including H3K9/18, H3K14, H4K5, H4K8, and H4K16 at the Il9 locus (1, 6). However, acetylation of H3K27 and H3K36, and H3K27 methylation are not affected by PU.1 deficiency. Decreased histone acetylation at the Il9 locus is coincident with decreased association of the histone acetyltransferase (HAT) proteins Gcn5 and PCAF, and increased association of histone deacetylase (HDAC) proteins HDAC1 and HDAC2 observed in the absence of PU.1 (6) . IL-9 production can be increased in Th9 cells by culture with the HDAC inhibitor trichostatin A, although importantly, PU.1 is required for this activity.
PU.1 interacts directly with Gcn5 and treatment of Th9 cells with siRNA for Gcn5 results in decreased amounts of IL-9 production. However, other cytokines produced by Th9 cells, including IL-10 and IL-21, are not affected either by trichostatin A treatment or by Gcn5 short interfering RNA (siRNA) (6) . This observation suggests that there is a specificity in the function of this pathway and that a PU.1-Gcn5 complex is critical in the regulation of IL-9 (6).
In human T cells, PU.1 similarly promotes IL-9 production. Human Th9 cells have increased expression of SPI1 (encoding PU.1) compared with Th2 cells (1). Decreasing PU.1 expression in Th9 cultures by siRNA also decreases IL9 expression (1, 27) . CD4 + IL-9 + and PU.1 + cells can be found in inflamed skin (40) . In peripheral blood samples from patients with atopic asthma, T cells that had the highest IL-9 production were also positive for expression of PU.1 (16) . Moreover, in Th9 cultures from atopic infants that demonstrated an increased propensity for the development of Th9 cells, there was coincident increased expression of SPI1 (41).
Together, these studies support a significant function for PU.1 in IL-9 production from human T cells. The expression of PU.1 and its ability to regulate IL-9 are also regulated by histone modifications. Human naive cord blood T cells are defective in their ability to differentiate into Th9 cells (27) . The Th9 deficiency correlates with diminished H3K4 methylation and increased H3K27 methylation of the SPI1 locus. Modulation of histone methylation at the PU.1 locus by cytokine treatment or using inhibitors of histone methyltransferases results in increased SPI1 and IL9 expression (27) . Modifying histone acetylation also affects PU.1 expression. Treatment of human Th9 cultures with curcumin, a histone acetylatransferase inhibitor, decreases expression of PU.1 (27) . In parallel, treatment of mouse Th9 cultures with trichostatin A (TSA), a histone deacetylase inhibitor, results in increases of both PU.1 and IL-9 expression (6). Importantly, TSA-induced IL-9 expression is dependent on the expression of PU.1, as TSA had no effect in PU.1-deficient Th9 cultures (6) . Together, these data support a central and conserved role for PU.1 in the regulation of IL-9 in both human and mouse Th9 cells (Fig. 1) .
STAT6, GATA3, and IRF4
STAT6 is phosphorylated throughout Th9 development in vitro, at levels very similar to those observed in Th2 development (10) . Not surprisingly, considering the importance of IL-4 in the development of Th9 cells, STAT6 is absolutely required for IL-9 production (2, 4, 10). Consistent with this, the STAT6 cofactor PARP-14, required for optimal Th2 development (42), is also required for optimal IL-9 production (10). In contrast with the requirement for STAT6, STAT3, which is activated during Th9 development and is required for normal Th2 development, is not required for Th9 development (10, 43) .
The identification of factors downstream of STAT6 seems the next critical question. One obvious candidate would be GATA3. In initial reports of the Th9 subset, it was shown that Th9 development was lost in GATA3-deficient cells, a phenotype similar to the requirement for GATA3 in Th2 development (2, 44, 45) . Gata3 mRNA rises through the differentiation period, although there is more of an increase in Th2 cultures toward the end of the 5-day differentiation period, and expression is STAT6 dependent (10) . Protein expression of GATA3 was slightly higher in Th9 cells than in Th2 cells, but GATA3 protein was not induced by anti-CD3 in Th9 cells as it was in Th2 cells (10) , suggesting that differences in GATA3 regulation between the subsets might be critical. In support of GATA3 expression being tightly regulated in Th9 cells, retroviral expression of GATA3 did not induce but rather repressed IL-9 production in wildtype Th9 cells, and although GATA3 induces Th2 cytokines in Stat6 À/À Th2 cultures, ectopic GATA3 expression did not rescue IL-9 expression in Stat6 À/À Th9 cultures (10, 38, 46) . Thus, although GATA3 contributes to the Th9 phenotype, it is not the primary STAT6 target. Another potential candidate is IRF4. IRF4 is required for Th9 development (3). IRF4-deficient T cells have defective Th9 development, and IRF4-deficient mice have diminished development of allergic inflammation, although this could be attributed to multilineage effects of IRF4 deficiency on Th2 and Th17 as well as Th9 cells (3, 47, 48) . IRF4 is also induced in human Th9 cultures and binds to the Il9 promoter (3) (Fig. 1) . Expression of IRF4 and binding of IRF4 to the Il9 promoter in Th9 cells is dependent on STAT6 (10). Furthermore, IRF4 transduction into wildtype Th9 cultures results in increased IL-9. However, transduction of IRF4 into Stat6 À/À cultures did not rescue IL-9 production.
Importantly, double transduction of IRF4 and GATA3 into Stat6 À/À Th9 cultures also does not rescue production of IL-9. Thus, although IRF4 and GATA3 clearly contribute to the STAT6-dependent development of Th9 cells, and the expression of IL-9, they are not the only relevant targets of STAT6 in Th9 differentiation.
NF-jB and NFAT
NF-jB is involved in cytokine regulation from a broad range of stimuli. Two different stimuli have been shown to require NF-jB for the induction of IL-9.
In its ability to induce IL-9 production, OX40 induces both the classical and alternative pathways of NF-jB activation (33) . However, the classical pathway, culminating in the activation of RelA-p50 heterodimers, is not required for OX40-induced IL-9, and ectopic expression of RelA-p50 does not induce IL-9. In contrast, ectopic expression of RelB-p52 induces endogenous IL-9 production, and activated an Il9 reporter. OX40-induced IL-9 was absent in p52-deficient Th9 cultures, and in Th9 cultures deficient in TRAF6, which was required for activation of the alternative pathway (33) . The specificity for the alternative NF-jB pathway may reflect the ability of a restricted set of NF-jB proteins to interact with other transcription factors at the Il9 promoter.
NF-jB, in cooperation with NFAT1 (nuclear factor of activated T cells), is required for TCR-induced IL-9 production from Th9 cells (36) . RelA (p65) was unique in the ability to induce an Il9 promoter reporter, and siRNA for RelA diminished production of IL-9. NFAT1 regulated access for RelA by altering histone modifications, and chromatin structure, at least partly through recruitment of the HAT p300 to the Il9 promoter. NFAT1 function was also required as cells deficient in NFAT1 demonstrated greatly reduced amounts of IL-9 production (36).
It is interesting that two different NF-jB proteins activate Il9 in different contexts. This may represent distinct promoter complexes following each stimulus. It will be interesting to see which complex is more important when additional stimuli are considered, including IL-25 and IL-33, which are known to activate NF-jB and induce IL-9 as mentioned above.
Notch, Smad, and RBP-Jj
Activation of the Notch pathway results in the release of the Notch intracellular domain (NICD), which acts as a cofactor with RBP-Jj in binding to target genes promoters. Elyaman et al. (14) demonstrated that Jagged2 activation results in increased levels of Smad3 protein and phospho-Smad3 activated by TGFb. NICD interacts with Smad3, potentially stabilizing expression. RBP-Jj and Smad3 bind directly to the Il9 promoter, with the greatest amounts in Th9 cultures. Moreover, Smad3 binding is virtually absent in Th9 cultures deficient in Notch signaling (14) . The cooperation between RBPJj, Smad3, and the NICD was also observed in an Il9 reporter assay (14) . Thus, TGFb and Notch signaling cooperate in the induction of IL-9.
Transcription factors in opposing T-helper lineages
As transcription factors promote the development of one lineage, they often inhibit cytokine and gene expression associated with other T-helper cell lineages. This paradigm is also true in the Th9 lineage. The Th1-associated transcription factors T-bet and Runx3 decrease expression of Il9 in Th9 cells (10) . The Treg cell lineage factor Foxp3 also decreases IL-9 production in Th9 cells (10) . Expression of both T-bet and Foxp3 are inhibited by IL-4/STAT6 signaling in developing Th9 cells (10) . IL-9 expression is also increased in Rorct-deficient mice (21) . Although the effects of the T-follicular helper lineage factor Bcl6 on IL-9 production have not been documented, the previously reported ability of Bcl6 to negatively regulate IL-4 signaling and GATA3 (49) suggests that it might be a negative regulator. Retroviral transduction of any of these factors into developing Th9 cells decreases production of IL-9 (10, author's unpublished results).
Are there really Th9 cells in vivo?
Given the relatively specific culture conditions that promote Th9 development and the relative difficulty in detecting IL-9-secreting T cells in vivo, either because of reagent limitations or because they display transient production of IL-9, it has been natural to question whether Th9 cells are a real in vivo subset. But the answer to the question, 'Are there really Th9 cells in vivo?' is simple. Yes.
There is considerable evidence of IL-9-secreting T cells from perhaps the most important 'model', humans. Th9 cells (CD4 + IL-9 + IL-13 À IFNc À ) are found in the peripheral blood of allergic patients, and this population is rare in non-allergic individuals (16) . Among cutaneous lymphocyte antigen-positive cells in the peripheral blood, there is a significant population of CD4 + IL-9 + IL-4 À IL-17 À IFNc À T cells (21) . IL-9-positive T cells are also found in both normal and inflamed skin (21, 40) . IL-9 responses can also be observed to specific antigen stimulation. In a population of atopic and non-atopic infants, stimulation with house dust mite extract or cat allergen resulted in greater production of IL-9, but not other Th cell cytokines, from cells isolated from infants that had been sensitized to the specific allergen (41) . Similar responses can be seen in response to pollen and dust mite allergen in peripheral blood mononuclear cell cultures of adult asthmatics and from T-cell clones isolated from sensitized patients (50) (51) (52) .
In murine systems, the detection of IL-9-secreting T cells has been more challenging, and the detection might depend on the model system used. Using an IL-9 fate reporter system, Th9 cells were detected using an ovalbumin (OVA)/ alum model of airway inflammation but not in a papain model of inflammation, and the reason for this difference could be due to the preferential activation of innate versus acquired immune cells by each stimuli (53) . The appearance of IL-9-secreting T cells seemed to be transient. However, using flow cytometry, IL-9-positive CD4 + T cells (that are negative for IL-13 and IFNc) can be identified during the development of house dust mite extract-induced lung inflammation (16) . IL-9-secreting T cells are also observed as melanoma-infiltrating lymphocytes (21) . Similarly, OVA stimulation induces Il9 expression from sensitized mice that is dependent on the expression of the Th9 transcription factor PU.1 (1) . The data thus far have focused on identifying Th9 cells in atopic patients and in mouse models of allergic disease. It has not yet been clearly established whether Th9 cells can be identified in other inflammatory diseases. However, the existence of IL-9-secreting T cells in allergic disease leads to the next logical question regarding the role of Th9 cells in disease.
What can Th9 cells do?
One approach for testing the in vivo function of T-helper subsets is to adoptively transfer T cells, either polyclonal or TCR transgenic populations, that have been polarized in vitro to a specific phenotype, such as Th9, after transfer cells can be challenged in vivo. Key to this approach is being able to show that IL-9 is an effector cytokine by coupling adoptive transfer experiments with antibody to block IL-9 function. This approach has been used for Th9 cells and they appear to be able to initiate a broad range of inflammatory diseases (Fig. 2) .
Allergic inflammation
Two reports have demonstrated that transferred Th9 cells lead to allergic inflammation in the lung. Transferred DO11.10 Th9 cells result in allergic airway disease following OVA challenge (3). Importantly, treatment of recipient mice with anti-IL-9 was able to block many features of the inflammation including airway hyperresponsiveness, eosinophil recruitment, and goblet cell metaplasia. Transferred OT-II Th9 cells were able to rescue the generation of allergic airway disease in Irf4 À/À mice, which, given the defects in 
Autoimmune disease
In the first description of Th9 cells, the overlapping production of the immunosuppressive cytokine IL-10 with IL-9, the latter having been linked with tolerance in some models (34) , led to the hypothesis that Th9 cells might be immunoregulatory (2) . However, in the classical colitis model to test for regulatory T-cell function, Th9 cells showed no regulatory function but rather initiated disease on their own, and exacerbated disease when injected with naive cells (2) . Thus, Th9 cells can promote intestinal inflammation. It is not clear whether IL-9 itself promotes intestinal inflammation, whether IL-9 impacts the production of additional cytokines from Th1 or Th17 cells that can promote intestinal inflammation, or whether Th9 cells directly acquire the ability to secrete other inflammatory cytokines in this model. Th9 cells also promote central nervous system inflammation. When transfer of MBP (myelin basic protein)-specific TCR transgenic Th9 cells was compared with the ability of other subsets of T-helper cells to induce EAE, clinical disease started earlier but was less severe in Th9 recipients than in Th17 recipients (20) . Moreover, the lesions that develop were distinct in recipients of Th9 cells compared with Th1 or Th17 recipients, suggesting parallel pathways to inflammatory disease resulting from transfer of each subset (20) . However, there are conflicting reports regarding the role for IL-9 in EAE. In some reports, blocking IL-9 or IL-9 signaling results in diminished pathology (54) (55) (56) . In contrast, IL-9 may also promote Treg function and inhibit EAE development (57) . A recent report demonstrating that the IL-9-inducing effect of the Notch ligand Jagged2 during EAE has different effects depending on when it is introduced to the model (14) suggests that context-dependent effects of IL-9 might impact the outcome of blocking effector functions on CNS disease.
Hen egg lysozyme (HEL)-specific Th9 cells result in ocular inflammation when HEL is expressed in the lens (7). However, in the experimental autoimmune uveitis (EAU) model, anti-IL-9 did not block inflammation, and most of the transferred Th9 cells were observed to be secreting IFNc during disease. The stability of the Th9 subset in vivo is still not clear, and in both EAE and EAU models, transferred Th9 cells acquire IFNc-secreting potential (7, 20) . Although this might suggest that Th9 cells do not cause disease and that it is the ability to become Th1 cells that is pathogenic, it is also possible that sequential secretion of IL-9 and IFNc results in different pathological outcomes. This concept is supported by the distinct pathology in recipients of Th1 and Th9 transferred cells (7, 20) .
Tumor immunity
Most recently, Th9 cells have been implicated in tumor immunity (21) . In examining tumor immunity in Rorc ) showed a similar function of transferred OVA-specific Th9 cells in several models of OVA-expressing melanoma. Endogenous immunity to melanoma was dependent on IL-9. The proposed mechanism of IL-9 activity was to induce local CCL20 production, thus enhancing the recruitment of dendritic cells and cytotoxic CD8 T cells to the tumor (58) . Additional mechanistic insight into the anti-tumor functions of Th9 cells will require further studies. 
Th9 function in patients
Definitively establishing in vivo functions of Th9 cells in patients is very difficult. However, several studies have demonstrated strong correlations of in vivo IL-9 with serum IgE concentration. In atopic patients, the percentages of IL-9-secreting T cells correlated with serum IgE in adults with asthma (16) . Similarly, the amounts of IL-9 secreted by ex vivo stimulated T cells correlated with serum IgE in atopic infants (41) . In agreement with a functional link to IgE production, some but not all studies have found an association of IL9 SNPs with serum IgE (59) (60) (61) (62) . Ongoing studies will hopefully define additional correlations of Th9 function with human physiology.
Function of IL-9 from other T-helper cell subsets
Although Th9 cells are specialized for production of IL-9, other cells may also be able to produce some IL-9 following an appropriate stimulus. TGFb can convert Th2 cells to IL-9-secreting cells (4) . The presence of TGFb in a culture also stimulates acute IL-9 production from several T-helper cells subsets, including Th17 cells (56) . The role of IL-9 in Th17-mediated disease is still unclear, with reports indicating both pro-and anti-inflammatory effects that may be disease or context dependent (14, 56, 57, 63, 64 ). An in vivo biological function of IL-9 has also been attributed to T-regulatory cells. A study linking mast cells to allogeneic skin transplantation tolerance observed IL-9 production from Treg cells (34) . IL-9 production by Treg cultures was induced following short-term stimulation with anti-CD3 and either anti-CD28 or anti-GITR, echoing the importance of costimulation in generating IL-9-secreting T cells, as discussed above (34) . Anti-IL-9 was able to block the function of transferred Tregs in this model (34) . Similar results were seen in a model of nephritis, wherein Tregsmediated immune suppression that was dependent on IL-9 and mast cells (65) . Precisely, how the Treg-IL-9-mast cell circuit promotes immune suppression has not been determined.
The caveat to the studies by Lu et al. and Eller et al. (34, 65) is that transferred Tregs were isolated based on positivity for CD4 and CD25, raising the issue that non-Tregs (Foxp3-negative cells) might have also been transferred. Subsequent studies have not observed IL-9 production from differentiated inducible Treg cultures (1, 10) , although it is possible that differentiating Treg cells, in the context of the proper stimulus, undergo an IL-9-secreting intermediate or that IL-9 production is restricted to natural Tregs.
Further studies should be able to define the source of IL-9 in these models.
Th9 stability
One issue that is still not well explored is the stability of the IL-9-secreting phenotype in vivo. Use of an Il9 reporter model suggested that IL-9 production is transient and that few of the former IL-9-secreting cells maintain IL-9 production (53) . Using a HEL-specific TCR transgenic model, studies suggest that antigen stimulation results in diminished IL-9 production in vitro and in vivo (7) . This may depend on the inflammatory environment, since several cytokines, including IFNc and IL-23, can alter Th9 cell phenotype or reduce IL-9 production (18-21). However, several studies described above have demonstrated that blocking IL-9 in recipients of transferred Th9 cells is able to block the function of the transferred cells (3, 20, 21, 58) , which would suggest that in the right environment Th9 cells are capable of maintaining IL-9-secreting potential, at least long enough to carry out biological function in vivo. Further studies with adoptive transfer models and reporter mice will be useful in refining our understanding of maintenance of the Th9 phenotype both in vitro and in vivo.
What are Th9 cells required for?
What Th9 cells are actually required for has been a question more difficult to answer. IL-9-and IL-9R-deficient mice, as well as antibodies to IL-9, have been used to define the role of this cytokine in several model system (reviewed in 8, 9). However, there are clearly cells other than Th9 cells, including mast cells and innate lymphoid cells (53, 66, 67) , that produce IL-9. Thus, although studies that block cytokine or cytokine receptor are critical for defining the cytokine function, they are not useful for defining the relevant source of that cytokine. Demonstrating that Th9 cells are the critical source of IL-9 would require lineage-specific deficiency or adoptive transfer experiments that have not yet been performed.
For other T-helper cells subsets, the approach has been to examine mice that are defective in one of the inducer cytokines, or in a transcription factor that is specific for that subset of Th cells. This has been a limitation for the Th9 lineage where a gene-deficient model with selective deficiency of only the Th9 lineage has not yet been defined. IL-4, its receptor, STAT6, and GATA3 are required for both Th2 and Th9 cell development (2, 4, 10) . IRF4 is required for Th2, Th9, and Th17 cell development (3, 47, 48) .
Notch signaling affects multiple T-helper lineages (14, 68, 69) . Thus, it has been difficult to examine disease models in mice that are only deficient in Th9 cells.
Initial reports utilized mice expressing a dominant negative TGFbRII transgene in CD4
+ T cells to demonstrate that Th9 cells are required for immunity to Trichuris muris (4). However, TGFbRII signaling is also required for Th17 and Treg development suggesting that this is not a lineage-restricted approach. Moreover, a subsequent report suggested that IL-9 production was not dramatically altered in mice expressing this transgene, and that altered immunity was dependent on increased IFNc production in the absence of TGFb signaling (15) . Perhaps the best 'Th9-deficient' model described thus far is using mice that are conditionally deficient in the transcription factor PU.1. Using mice that lack PU.1 expression in T cells, allergic inflammation is decreased, and in vivo IL-9 production is diminished (1). There is a modest increase in peripheral Th2 responses in the absence of PU.1 expression in T cells, but production of Th1 or Th17 cytokines in the periphery is not altered (1, 37) . Thus, although the effects of PU.1 deficiency in T cells are not entirely restricted to Th9 cells, this model still facilitates the most accurate analysis of the effects of Th9 deficiency on inflammation. The phenotype of allergic inflammation in mice that lack PU.1 expression in T cells closely paralleled that of mice where IL-9 was neutralized (1).
The greatest evidence for a role of Th9 cells in vivo, from mouse models and from correlation studies in patients, is in allergic disease. Based on the requirement for various Th2 cytokines (70), Th9 cells likely collaborate with Th2 cells in regulating allergic inflammation. Whether these two subsets promote distinct aspects of allergic disease or whether they have overlapping functions is still not clear. Defining the role of Th9 cells in these and other diseases awaits broader usage of mice with PU.1-deficient T cells or the development of additional mouse models that specifically lack the development of Th9 cells.
How does IL-9 promote inflammation?
Despite the broad ability of IL-9 to impact multiple types of inflammation, it is not clear how it functions. IL-9, like many cytokines, has pleiotropic effects. The earliest defined function may be one of the more important. IL-9 promotes survival of CD4 + T cells, mast cells, and other cells (8, 9) , and it therefore seems reasonable that this function might be capable of impacting the multiple cell types involved in generating the spectrum of inflammatory immunity. A recent commentary has even proposed that this is the primary function of IL-9 (71). Indeed, there is ample evidence that IL-9 performs this function in vivo, including expansion of Th17 and Treg cells under various conditions (14, 34, 57, 65) . However, a simple survival signal does not explain the more specific effects of IL-9 in vivo and in vitro. Transgenic expression of IL-9 in the lung or intestine leads specifically to allergic and not other types of inflammation (72) (73) (74) (75) . Moreover, adoptive transfer of Th9 cells has shown that they can have divergent function from other transferred subsets in models of tumor immunity, EAE, and allergic airway disease (16, 20, 21) . In vitro and in vivo, IL-9 stimulation results in the induction of chemokines such as eotaxin in smooth muscle cells or in goblet cell metaplasia, suggesting that there is specific induction of genetic programs (76) (77) (78) .
Some or perhaps even many of these observations can be linked to growth effects of IL-9 on mast cells in vivo (16, 79, 80) . IL-9 not only stimulates mast cell growth and expansion but also stimulates changes in mast cell gene expression that might alter responsiveness to other stimuli (81) . Thus, IL-9 stimulation of mast cells might specifically result in allergic inflammation or promote mast cell-dependent functions in anti-tumor responses and inflammatory disease. In some models, the in vivo effects of IL-9 rely on other cytokines. For example, in the lung-specific IL-9 transgenic models, inflammation depends on IL-13 (82) . However, the source of IL-13 is not known and could be mast cells, innate lymphoid cells, or Th2 cells. Thus, defining the relevant IL-9-responding cells will be critical for understanding how IL-9 promotes inflammation. IL-9 clearly has effects in models of allergic inflammation that are mast cell independent. OVA/alum-induced inflammation develops in the absence of mast cells, and yet inflammation is diminished in mice treated with blocking antibody to IL-9 and in mice lacking PU.1 expression in T cells, which results in diminished Th9 cells (1, 31, 83) . In these models, the direct effects of IL-9 on lymphoid or tissue-resident cells may be more important. Defining these functions is likely complicated by some overlap in the functions of Th2 and Th9 cytokines, and the demonstration that IL-4 can mediate type II inflammation in the absence of IL-9 and other Th2 cytokines (84) . Among the various models of inflammation, there is likely specificity of what cells produce IL-9 and which cells respond to IL-9. The central question will be which of these models reflect how Th9 cells function in human disease.
Concluding comments
Despite a recent increase in the number of reports on IL-9-producing cells, IL-9 is still an understudied cytokine. It languished for many years, misrepresented as just another Th2 cytokine, and although a vast number of biological functions were ascribed to it, how it contributed to immune responses was unclear. The more recent description of a specialized subset of T cells that produce IL-9 has resulted in a beachhead to further explore IL-9 function in vivo. Th9 cells develop in response to a complex cytokine milieu. Several costimulatory signals provided by antigen-presenting cells also impact the abundance of IL-9 production. Both cytokines and costimulatory signals lead to the activation of transcription factors that directly or indirectly regulate Il9 transcription. A more detailed analysis of Il9 regulation will provide further clues about the development of this subset, and how regulation of IL-9 might be therapeutically altered. Although studies on the regulation of Il9 have provided important insight into the development of the Th9 subset, it is still not clear if there are genes that are essential for Th9 function, aside from the specialization for IL-9 production. Moreover, whether the same transcription factors that promote Il9 expression also activate a larger Th9 genetic program is unknown. 
